title: Interobserver variability in intraductal papillary mucinous neoplasm subtypes and application of their mucin immunoprofiles.
abstract: Intraductal papillary mucinous neoplasm is considered a precursor lesion to pancreatic adenocarcinoma. These are further classified into four histologic subtypes: gastric, intestinal, pancreatobiliary, and oncocytic. The first aim of this study was to assess the interobserver variability among five gastrointestinal pathologists in diagnosing intraductal papillary mucinous neoplasm subtypes by morphology alone. The second aim of the study was to compare intraductal papillary mucinous neoplasm subtypes, which received consensus diagnoses (≥80% agreement) with their respective mucin immunoprofiles (MUC1, MUC2, MUC5AC, MUC6, and CDX2). A consensus histologic subtype was reached in 58% of cases (29/50) among the five gastrointestinal pathologists. Overall there was moderate agreement (κ=0.41, P<0.01) in subtyping intraductal papillary mucinous neoplasms without the use of immunohistochemistry. The histologic subtype with the best interobserver agreement was intestinal type (κ=0.56, P<0.01) followed by pancreatobiliary, gastric, mixed, and oncocytic types (κ=0.43, P<0.01; κ=0.38, P<0.01; κ=0.17, P<0.01; κ=0.08, P<0.04, respectively). Both kappa values for mixed and oncocytic subtypes were likely artificially low due to the underrepresentation of these subtypes in this study and not a true indication of poor interobserver agreement. Following an intradepartmental consensus meeting between two gastrointestinal pathologists, 68% of cases (34/50) received a consensus intraductal papillary mucinous neoplasm subtype. Sixty-nine percent of cases (11/16) that did not receive a consensus intraductal papillary mucinous neoplasm subtype could be classified based on their respective immunoprofiles. Standardizing the use of immunohistochemistry with a mucin immunopanel (MUC1, MUC2, MUC5AC, and MUC6) may improve the agreement of diagnosing intraductal papillary mucinous neoplasm histologic subtypes.
authors.affiliation: Department of Pathology, University of Chicago, Chicago, IL, USA.
authors.forename: Heewon A
authors.initials: HA
authors.lastname: Kwak
authors.affiliation: Department of Pathology, University of Florida, Gainesville, FL, USA.
authors.forename: Xiuli
authors.initials: X
authors.lastname: Liu
authors.affiliation: Department of Pathology, Cleveland Clinic Foundation, Cleveland, OH, USA.
authors.forename: Daniela S
authors.initials: DS
authors.lastname: Allende
authors.affiliation: Department of Pathology, Mayo Clinic, Scottsdale, AZ, USA.
authors.forename: Rish K
authors.initials: RK
authors.lastname: Pai
authors.affiliation: Department of Pathology, University of Chicago, Chicago, IL, USA.
authors.forename: John
authors.initials: J
authors.lastname: Hart
authors.affiliation: Department of Pathology, University of Chicago, Chicago, IL, USA.
authors.forename: Shu-Yuan
authors.initials: SY
authors.lastname: Xiao
mesh_terms: D014408:Biomarkers, Tumor / Q000032:analysis; D001706:Biopsy; D000071616:CDX2 Transcription Factor / Q000032:analysis; D006801:Humans; D007150:Immunohistochemistry; D009077:Mucins / Q000032:analysis; D018297:Neoplasms, Cystic, Mucinous, and Serous / Q000737:chemistry / Q000145:classification / Q000473:pathology*; D015588:Observer Variation; D010190:Pancreatic Neoplasms / Q000737:chemistry / Q000145:classification / Q000473:pathology*; D011237:Predictive Value of Tests
chemical_list: D014408:Biomarkers, Tumor; D000071616:CDX2 Transcription Factor; C491270:CDX2 protein, human; D009077:Mucins